Novartis' decision to dissolve its Cell and Gene Therapy unit was driven by a strategic pivot, rather than abandonment. Moreover, leveraging a pharma company-based actionable org chart offers a comprehensive view of why Novartis dissolved its Cell and Gene Therapy unit.

The actionable sales intelligence tool goes beyond the surface to illustrate how this move fits into the broader organizational strategy, potentially indicating a redirection rather than abandonment of efforts in cell and gene therapies. This understanding is crucial for stakeholders seeking to engage with Novartis and explore its future directions in innovative therapies.

You can view Org Charts HERE.